ELIZABETH BAUMANN: Open Payments
NPI 1356961817 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,571 in 68 payments from 16 companies in 2025. Trend: 2023 $2,412 · 2024 $2,621 · 2025 $1,571
Food & beverage: $1,571
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $286 |
| AstraZeneca Pharmaceuticals LP | 9 | $189 |
| Mallinckrodt Hospital Products Inc. | 7 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $148 |
| GENZYME CORPORATION | 6 | $132 |
| Grifols USA, LLC | 5 | $120 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| CSL Behring | 3 | $72 |
| Philips North America LLC | 3 | $63 |
Products named: DUPIXENT, NUCALA, ACTHAR, GLASSIA, Prolastin-C Liquid, OFEV, TRELEGY ELLIPTA, Hizentra.
Industry payments across AL — which companies pay providers there.
